

Alessandro Carugo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/87222/publications.pdf>

Version: 2024-02-01

26
papers

2,207
citations

394286

19
h-index

552653

26
g-index

28
all docs

28
docs citations

28
times ranked

4881
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , 2014, 514, 628-632.	13.7	998
2	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	13.7	129
3	In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 133-147.	2.9	114
4	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , 2017, 542, 362-366.	13.7	105
5	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. <i>Science</i> , 2021, 373, eabj0486.	6.0	99
6	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2015, 27, 644-657.	7.7	85
7	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	7.7	74
8	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. <i>Cell Reports</i> , 2019, 26, 1518-1532.e9.	2.9	70
9	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.4	68
10	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
11	<i>In Vivo</i> Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. <i>Cancer Discovery</i> , 2016, 6, 650-663.	7.7	59
12	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	42
13	RNAi screens identify CHD4 as an essential gene in breast cancer growth. <i>Oncotarget</i> , 2016, 7, 80901-80915.	0.8	37
14	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. <i>Cancers</i> , 2019, 11, 1321.	1.7	34
15	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	5.8	31
16	The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?. <i>Cancers</i> , 2019, 11, 1574.	1.7	28
17	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. <i>Cancer Research</i> , 2021, 81, 4054-4065.	0.4	24
18	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , 2021, 11, 2904-2923.	7.7	23

#	ARTICLE	IF	CITATIONS
19	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
20	Loss of ARID1A Promotes Epithelial to Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. <i>Cancer Research</i> , 2021, 81, 332-343.	0.4	22
21	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. <i>Cancers</i> , 2019, 11, 462.	1.7	20
22	Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. <i>Oncotarget</i> , 2019, 10, 3979-3981.	0.8	15
23	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. <i>Cancers</i> , 2021, 13, 6022.	1.7	14
24	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	12
25	Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. <i>Oncogene</i> , 2021, 40, 4425-4439.	2.6	11
26	Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. <i>Cancers</i> , 2021, 13, 3805.	1.7	6